About Our Team
Helping to improve patient care and outcomes
with products that provide early and specific
insights into clinical conditions.
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark, with US headquarters in Chicago, and is listed on the NASDAQ Copenhagen stock exchange. [CPH: BIOPOR]
Peter Mørch Eriksen
Peter Mørch Eriksen was appointed CEO of BioPorto in July 2013. Peter has more than 20 years of experience in medtech/life science in Denmark and abroad. Prior to joining BioPorto, he was CEO of Sense A/S and before this role, he held positions as a Vice President of Medtronic in both the USA and Denmark. From these positions Peter brings extensive experience in creating growth, restructuring and funding in technology intensive and complex companies. He has an accounting background supplemented by courses in management. In addition to being CEO of BioPorto, Peter chairs the board of FluoGuide, and is a member of Lund University Advisory Board. He also serves on the Medical Device and Diagnostics Advisory Committee of Cincinnati Children’s Hospital Medical Center in Ohio, US.
Ole Larsen was appointed CFO of BioPorto in June 2018. He brings comprehensive industrial and financial knowledge to BioPorto as an experienced executive in international health care and media companies. Most recently from Bavarian Nordic A/S, a Nasdaq-listed Danish biotechnology company focused on cancer immunotherapies and vaccines for infectious diseases. Since 2008, Ole served as Executive Vice President and CFO and was responsible for Finance, IR and IT. Prior to this, he held CFO positions at two of the largest Danish and Nordic media groups, Nordisk Film and Berlingske Tidende. Ole holds a MSc in Economics from Copenhagen Business School.
Jan Kuhlmann Andersen
Jan Kuhlmann Andersen was appointed COO of BioPorto in August 2016. Jan is an experienced executive having worked in sales in the life sciences since 1995, primarily in US-owned companies such as FMC, Cambrex, Fisher Scientific and Thermo Fisher. From 2007 and until joining BioPorto, Jan was Vice President, Sales & Marketing, in the Animal Health & Nutrition division in Chr. Hansen A/S. He holds a PhD in Immunology and a MSc in Biology, both from the University of Copenhagen. Jan also serves as the Chairman of Cytovac A/S and was previously a board member of Noscomed Medical Supply A/S, the French life science company Cell Made and of BioPorto A/S from 2015 to 2016.
Christopher Bird was appointed Chief Medical Officer of BioPorto in August 2019. Christopher has a robust scientific background and a track record of delivering strong results in business development, finance, sales, and marketing. He most recently served as Head of North American Medical and Scientific Affairs at Roche Diagnostics Corp., where he had responsibility for strategy and execution of all clinical education, study management and field support during his 10 year tenure. Chris has a BA in Physiology from Brigham Young University, a MA in Biochemistry and Molecular Biology from University of California Los Angeles, and a DPhil in Molecular Immunology from Oxford University, where he was an Abraham Scholar.
President, BioPorto Diagnostics, Inc.
Amy Winslow was appointed President of BioPorto Diagnostics, Inc. in April 2019. She is an experienced diagnostics executive, who most recently served as President and CEO of Magellan Diagnostics, a Boston-based point-of-care diagnostics company. While at Magellan, she lead the company’s restructuring for growth, increased profitability, built a dedicated commercial team, and ultimately ran a successful sale of the company to Meridian Bioscience, Inc. Prior to Magellan, among other roles, Amy served as VP Marketing for Athena Diagnostics, a neurodiagnostic specialty laboratory testing business that was later acquired by Quest Diagnostics and as Marketing Manager at Genyzme Transgenics. She has an MBA from Harvard Business School and a BA in Biology from Brown University. Amy serves on several non-profit boards, including the Boston Museum of Science and the Brigham and Women’s Physician’s Organization.
Chairman of the Board
Thomas Magnussen is the Chairman of the Board of Directors and has served on BioPorto’s Board since 2013.
Thomas is a successful serial entrepreneur with expertise in global business and commercialization strategies from industries ranging from nanotechnology, to Information and Communication Technologies (ICT) to medical technology. He is the Chairman and co-founder and partner in QuantumWise A/S and Zylinc A/S, respectively. Thomas holds an MBA from INSEAD and a PhD and MSc from the Technical University of Denmark.
Torben A. Nielsen
Vice Chairman of the Board
Torben A. Nielsen has been a member of the Board of Directors since 2013. He is experienced in global finance and M&A, having held senior positions in the financial sector for over 30 years, including roles in both New York and London. From 1998 to 2008 he was member of the executive management in Sydbank A/S, where he was responsible for several business areas, including asset management, capital markets, foreign and treasury. From 2008 to 2012 he was the CEO of BankInvest A/S. He has concurrently held several national and international board positions, including at NASDAQ OMX.
Kirsten Aarup Drejer
Kirsten Aarup Drejer joined BioPorto’s Board of Directors in 2017. She is co-founder of Symphogen A/S, a biopharmaceutical company focused on the innovative therapeutic utilization of antibodies. From 2000 until 2016, Kirsten was CEO of Symphogen A/S. Prior to starting Symphogen, she held a number of scientific and managerial positions within Novo Nordisk A/S. Kirsten also serves as a member of the Board of Directors of Symphogen A/S and the Danish Growth Fund and has previously been a member of the Board of Directors of Danisco A/S, among others. She also participates in numerous advisory boards at the University of Copenhagen and the Copenhagen Business School. Kirsten was awarded the prize of ”Biotech Builder of the Year” in 2003 and ”Entrepreneur of the Year, Biotech” in 2007. She has an MSc and PhD in Pharmacology from the University of Copenhagen.
Christopher Lindop joined BioPorto’s Board in August 2019. He has over 15 years of experience in senior finance leadership roles with public healthcare companies and currently serves as the CFO of Quotient Limited, a developer and manufacturer of transfusion diagnostic products. Previously Chris was CFO of Haemonetics Corporation and CFO of Inverness Medical Innovations. In addition to his executive experience, Mr Lindop was a non-executive director of Parexel International Corporation (NASDAQ: PRXL) from 2006, where he was chairman of the audit and finance committee and a member of the nominating and governance committee until its sale. Chris has also served as an audit partner with the Boston office of Ernst & Young LLP and with the Boston office of Arthur Andersen LLP. He holds a BA in Business from the University of Strathclyde (Scotland).
Michael S. Singer
Michael S. Singer has been a member of BioPorto’s Board of Directors since August 2019. He is currently Chief Scientific Officer (CSO) and co-founder of Cartesian Therapeutics, Inc., a US biotech company developing novel cellular immunotherapies to cure cancer. Prior to founding Cartesian, he was co-founder and CSO of Topokine Therapeutics, Inc., and of Health Honors Corporation. Michael’s experience also includes leading Translational Medicine at Novartis Institutes for Biomedical Research. He is a board-certified ophthalmologist and has been admitted to practice patent law. He has served as a Surgeon in the Veterans Health Administration and teaches at Harvard Medical School. Michael completed residency at Harvard and holds a BS, MD, and PhD from Yale University.